ACG Clinical Guideline: Management of Crohn’s Disease in Adults

By G. Lichtenstein, E. Loftus, K. Isaacs, M. Regueiro, L. Gerson, Bruce E. Sands. American Journal of Gastroenterology, 2018

1,274 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis (2019, neutral): “Infliximab, adalimumab, and certolizumab are approved for the treatment of Crohn’s disease, and infliximab, adalimumab, and golimumab are approved for the treatment of ulcerative colitis, while etanercept is not approved for either condition (42,43).”
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. (2019, background): “However, since thiopurines have a slow onset of action [8–12 weeks] 43 and are effective for maintaining remission in steroid-dependent CD patients [see Maintenance, 6.2.1., Recommendation 2.2.]”
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry (2020, neutral): “Overall 525 363 (69) 161 (31) 24 (5) 21 (4) 16 (3) 37 (7) Age, y 0–9 3 3 (100) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 10–19 26 23 (88) 3 (12) 0 (0) 0 (0) 0 (0) 0 (0) 20–29 116 93 (80) 23 (20) 2 (2) 1 (1) 0 (0) 2 (2) 30–39 108 87 (81) 20 (19) 4 (4) 2 (2) 1 (1) 4 (4) 40–49 95 64 (67) 31 (33) 4 (4) 3 (3) 2 (2) ”